Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies

Friday, October 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the role of PRMT5 inhibitors in regulating DNA damage repair pathways in cancer cells. It highlights their potential to improve responses to PARP inhibitors and chemotherapies. This research suggests that targeting PRMT5 could enhance treatment efficacy for cancer patients, offering a new avenue for therapeutic strategies.
Price reaction · baseline $2.32 (2023-10-19 close) · hit pre-market · 5 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRMT5 inhibitors show promise in regulating DNA damage repair pathways.
  • Improved response to PARP inhibition suggests enhanced cancer treatment efficacy.
  • Potential to improve outcomes for patients undergoing chemotherapy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Jack Carter, Michael Hulse, Monisha Sivakumar, Jessica Burtell, Venkat Thodima, Min Wang, Anjana Agarwal, Komali Vykuntam, Jacob Spruance, Neha Bhagwat, Joseph Rager, Bruce A Ruggeri, Peggy Scherle, Koichi Ito
DOI: 10.1158/2767-9764.CRC-23-0070

Frequently Asked Questions

What are PRMT5 inhibitors?

PRMT5 inhibitors are compounds that target the PRMT5 enzyme, potentially regulating DNA damage repair pathways in cancer cells.

How do PRMT5 inhibitors affect cancer treatment?

They may improve the effectiveness of PARP inhibitors and chemotherapies, enhancing overall treatment responses.

What role do PRMT5 inhibitors play in DNA repair?

PRMT5 inhibitors regulate DNA damage repair pathways, which are crucial for maintaining genomic stability in cancer cells.

Can PRMT5 inhibitors be used with chemotherapy?

Yes, the research suggests that PRMT5 inhibitors can improve responses to chemotherapy in cancer treatment.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRMT5 DNA damage repair PARP inhibition chemotherapy cancer therapy
Last updated: Oct 20, 2023

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →